« How Not to Do It: Acetylene Cylinders |
| The Memory Goes Because. . .the Acetyl Groups Go? »
May 17, 2010
Modeling in Drug Discovery: Questions?
I'll have the opportunity to sit in on a few talks during a conference on free energy calculations in drug design. Since I'm not a computational guy myself, I'll be picking my sessions carefully, but I am interested in hearing what the state of the art is.
If we could just walk right up and calculate the free energies of binding events reliably, that would mean that the era of high throughput screening would begin to come to its end - well, in the physical world, anyway. Depending on how lengthy the computations needed to be, we could (in theory) just sit back and let the hardware hum while it ran through all the compounds we could think up - then we'd come back in on Monday and see who the winners were. Despite what some of you outside the field of medicinal chemistry might have read, we are not exactly to this point yet. That phrase "in theory" covers an awful lot of ground. But progress is apparently being made (here's a recent paper (PDF) with background).
So here's a question for the readership: what would you most want such calculations to be able to do for you? What would convince you that they're actually believable? And how close to you think that we actually are to that? Your comments will go directly to the ears of a roomful of high-powered modelers, so feel free to unload.
That thought of a roomful of computational chemists, though, reminds me inexorably of a story about Robert Oppenheimer that Freeman Dyson retells here. At a theoretical physics conference in Vancouver, the attendees were on a boat ride among the islands when the weather turned impenetrably foggy. Someone asked what the consequences for physics would be if the boat sank, and Oppenheimer instantly said "It wouldn't do any permanent good". There, that should ensure me a warm welcome at the meeting!
+ TrackBacks (0) | Category: In Silico
POST A COMMENT
- RELATED ENTRIES
- Amgen Cuts Hard
- Abandoned Pharma
- Targacept Comes Up Empty, Yet Again
- Summer Blogging
- The Antibiotic Gap: It's All of the Above
- Phenotypic Assays in Cancer Drug Discovery
- Neratinib Comes Through For Puma
- How Many Biopharma Employees Would Rather Be Working Somewhere Else?